REMARKS

The Specification has been amended to include SEQ ID numbers which were omitted at the time of filing and renumber erroneously numbered sequences.

Attached hereto is a marked-up version of changes made to the Specification by the current amendemnt. The attached page is captioned "**Version with markings to show changes made**".

The undersigned hereby states that the computer readable form copy (CFR copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **397272000700**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: March 13, 2002   By: _____
                                        Kawai Lau
                                        Registration No. 44,461

                                        Morrison & Foerster LLP
                                        3811 Valley Centre Drive
                                        Suite 500
                                        San Diego, California 92130-2332
                                        Telephone: (858) 720-5178
                                        Facsimile: (858) 720-5125

In the Specification:

Paragraph beginning at page 39, line 4, has been amended as follows:

Accordingly, the present invention also provides a vector, which, if DNA, comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 4, 5, 6, [7,] 15, 16, [17 and 18] and, which, if RNA, comprises a nucleotide sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:4, 5, 6[, 7].

Paragraph beginning at page 39, line 27, has been amended as follows:

Also provided by the present invention is a method of modifying a vector. The method comprises obtaining a vector and introducing into the vector a nucleotide sequence selected from the group consisting of the DNA sequences of SEQ ID NOS:2, 3, 4, 5, 6, 14, in which at least one N is mutated, 15 and 16, if the vector is DNA, and a nucleotide sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 4, 5, 6, [7,] 15, 16, [17 and 18] if the vector is RNA.

Paragraph beginning at page 40, line 1, has been amended as follows:

Also provided is an isolated and purified nucleic acid molecule selected from the group consisting of a DNA molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 5, 6, 14, in which at least one N is mutated, 15 and 16 and a RNA molecule comprising a nucleotide sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 6, [7,] 15, 16[, 17 and 18].

Paragraph beginning at page 69, line 38, has been amended as follows:

Additional examples of splice-donor site combinations, as well as a concensus sequence, are provided below. While all may be used, the HIV major, HIV-1 env, HIV-2 major, and analog splice-donor combinations are preferred.

sd-82707

CONCENSUS SPLICE DONOR:	NNNNAGGTAAGTNNN	(SEQ ID NO:7)
BETA-GLOBIN SPLICE DONOR:	NGGGCAGGTAAGTAT	(SEQ ID NO:8)
HIV MAJOR SPLICE DONOR:	NNGACTGGTGAGTAN	(SEQ ID NO:9)
HIV-1 ENV SPLICE DONOR :	AAAGCAGTAAGTAGT	(SEQ ID NO:10)
HIV-2 ENV SPLICE DONOR:	AGACAAGTGAGTAAG	(SEQ ID NO:11)
HIV-2 MAJOR SPLICE DONOR:	NNGAAGGTAAGTGCN	(SEQ ID NO:12)
ANALOG SPLICE DONOR:	CTTCAGGGTGAGTTNN	(SEQ ID NO:17)

Paragraph beginning at page 70, line 19, has been amended as follows:

This example describes the amino acid sequence of a chimeric HIV CTL epitope for use in the practice of the invention. The sequence (SEQ ID NO:18) contains a first methionine (M) to initiate translation followed by various contiguous subsequences corresponding to p17, p24, p15, Pol, Rev, gp120env, gp41env, and nef, respectively.

sd-82707